A total of 190 patients were enrolled in the prospective phase 2 clinical trial of anti–PD-1 monotherapy for patients with RM-NPC; 11 patients without data on baseline EBV DNA titers were excluded from this analysis. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.